These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 16719061)

  • 21. Gene- and cell-based approaches for neurodegenerative disease.
    Urbaniak Hunter K; Yarbrough C; Ciacci J
    Adv Exp Med Biol; 2010; 671():117-30. PubMed ID: 20455500
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Growth factor gene therapy for Alzheimer disease.
    Tuszynski MH; U HS; Alksne J; Bakay RA; Pay MM; Merrill D; Thal LJ
    Neurosurg Focus; 2002 Nov; 13(5):e5. PubMed ID: 15769074
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Versatile somatic gene transfer for modeling neurodegenerative diseases.
    Klein RL; Wang DB; King MA
    Neurotox Res; 2009 Oct; 16(3):329-42. PubMed ID: 19669852
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gene therapy for neurological disease.
    Tuszynski MH
    Expert Opin Biol Ther; 2003 Aug; 3(5):815-28. PubMed ID: 12880381
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospects for gene therapy in inherited neurodegenerative diseases.
    Cardone M
    Curr Opin Neurol; 2007 Apr; 20(2):151-8. PubMed ID: 17351484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Nerve growth factor in neurodegeneration and neurorestorative therapy].
    Lorigados-Pedre L; Bergado-Rosado J
    Rev Neurol; 2004 May 16-31; 38(10):957-71. PubMed ID: 15175980
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.
    Mufson EJ; Counts SE; Perez SE; Ginsberg SD
    Expert Rev Neurother; 2008 Nov; 8(11):1703-18. PubMed ID: 18986241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progress and prospects: Immunobiology of gene therapy for neurodegenerative disease: prospects and risks.
    McMenamin MM; Wood MJ
    Gene Ther; 2010 Apr; 17(4):448-58. PubMed ID: 20147982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro analysis of mouse neural stem cells genetically modified to stably express human NGF by a novel multigenic viral expression system.
    Cenciarelli C; Budoni M; Mercanti D; Fernandez E; Pallini R; Aloe L; Cimino V; Maira G; Casalbore P
    Neurol Res; 2006 Jul; 28(5):505-12. PubMed ID: 16808880
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of rAAV2-mediated NGF gene delivery in adult and aged rats.
    Wu K; Meyers CA; Guerra NK; King MA; Meyer EM
    Mol Ther; 2004 Feb; 9(2):262-9. PubMed ID: 14759810
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Promoter-activated expression of nerve growth factor for treatment of neurodegenerative diseases.
    Wyman T; Rohrer D; Kirigiti P; Nichols H; Pilcher K; Nilaver G; Machida C
    Gene Ther; 1999 Oct; 6(10):1648-60. PubMed ID: 10516713
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease.
    Mandel RJ
    Curr Opin Mol Ther; 2010 Apr; 12(2):240-7. PubMed ID: 20373268
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Perinatal gene delivery to the CNS.
    Rahim AA; Buckley SM; Chan JK; Peebles DM; Waddington SN
    Ther Deliv; 2011 Apr; 2(4):483-91. PubMed ID: 22826856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new tool in the battle against Alzheimer's disease and aging: ex vivo gene therapy.
    Ebert AD; Svendsen CN
    Rejuvenation Res; 2005; 8(3):131-4. PubMed ID: 16144466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene Therapy Approach with an Emphasis on Growth Factors: Theoretical and Clinical Outcomes in Neurodegenerative Diseases.
    Parambi DGT; Alharbi KS; Kumar R; Harilal S; Batiha GE; Cruz-Martins N; Magdy O; Musa A; Panda DS; Mathew B
    Mol Neurobiol; 2022 Jan; 59(1):191-233. PubMed ID: 34655056
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lentivirus-mediated gene transfer to the central nervous system: therapeutic and research applications.
    Wong LF; Goodhead L; Prat C; Mitrophanous KA; Kingsman SM; Mazarakis ND
    Hum Gene Ther; 2006 Jan; 17(1):1-9. PubMed ID: 16409120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RNAi medicine for the brain: progresses and challenges.
    Boudreau RL; Rodríguez-Lebrón E; Davidson BL
    Hum Mol Genet; 2011 Apr; 20(R1):R21-7. PubMed ID: 21459775
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MicroRNA (miRNA) Signaling in the Human CNS in Sporadic Alzheimer's Disease (AD)-Novel and Unique Pathological Features.
    Zhao Y; Pogue AI; Lukiw WJ
    Int J Mol Sci; 2015 Dec; 16(12):30105-16. PubMed ID: 26694372
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synaptic vulnerability in neurodegenerative disease.
    Wishart TM; Parson SH; Gillingwater TH
    J Neuropathol Exp Neurol; 2006 Aug; 65(8):733-9. PubMed ID: 16896307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changes in CSF cholinergic biomarkers in response to cell therapy with NGF in patients with Alzheimer's disease.
    Karami A; Eyjolfsdottir H; Vijayaraghavan S; Lind G; Almqvist P; Kadir A; Linderoth B; Andreasen N; Blennow K; Wall A; Westman E; Ferreira D; Kristoffersen Wiberg M; Wahlund LO; Seiger Å; Nordberg A; Wahlberg L; Darreh-Shori T; Eriksdotter M
    Alzheimers Dement; 2015 Nov; 11(11):1316-28. PubMed ID: 25676388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.